An orphan drug 'Jakavi' has got through the barrier of the insurance benefit

‘Jakavi’, which is sincerelywanted by myelofibrosis patients, has finally got throughthe barrier of the insurance benefit evaluation.

Jakavi approved in January 2013was revaluated asa non-insurance benefit product both in June 2013 and January 2014; however, after the third effort on the evaluation, it finally passed the entry of its ‘beneficialization’.

While the Drug Insurance Benefit Evalu...